Sesquiterpenes are natural terpenes containing 15 carbon atoms. They are widely used in the perfume, pharmaceutical, and biofuel industries due to their remarkable biological activities. The traditional production of sesquiterpenes relies on chemical synthesis or plant extraction, which has the disadvantages of low yields and waste of resources. The construction of microbial cell factories for the efficient synthesis of sesquiterpenes by means of synthetic biology provides a new option. In recent years, with the development of metabolic engineering and synthetic biology, the heterologous synthesis of a variety of sesquiterpenes has been successfully achieved by metabolic engineering of the oleaginous yeast, Yarrowia lipolytica. In this paper, we review the research progress in the heterologous synthesis of different sesquiterpenes by Y. lipolytica, discuss the synthetic biology strategies commonly used in this field, and make an outlook on the research directions and engineering approaches to further enhance the sesquiterpene yield in this host. This paper provides a reference for strategies such as synergistic optimization of synthetic biology and metabolic engineering, enhanced precursors, and opens up new directions for the application of synthetic biology in green chemistry and sustainable production.
Yarrowia/genetics* ; Sesquiterpenes/metabolism* ; Metabolic Engineering/methods* ; Synthetic Biology/methods*

CD20 is a classic marker expressed by B cells. However, recent studies have found that CD20 is also dimly expressed on a small subset of CD3 +T cells, and the CD20 +T cells play an important proinflammatory role in multiple sclerosis (MS). Anti-CD20 monoclonal antibodies selectively deplete CD20 +T cells and effectively suppress inflammatory disease activity. Although CD20 +T cells have received increasing attention, the understanding of these cells is currently still in its infancy. This article provides an overview of the current knowledge about advanced progress of CD20 +T cells as well as their roles in MS.

OBJECTIVE To provide reference for exploring alternative resources of Gentiana rigescens from the plants of Gentiana. METHODS The contents of four components （gentiopicroside， swertiamarin， swertioside and amarogentin） in the roots and rhizomes from 3 plants of Gentiana （G. rigescens， G. cephalantha， G. delavayi） were determined by high-performance liquid chromatography （HPLC）. The chemical compositions in the above roots and rhizomes were identified by ultra-performance liquid chromatography electrospray ionization quarter-time of flight mass spectrometry （UPLC-ESI-Q-TOF-MS）， and the differences were analyzed by principal component analysis （PCA）. RESULTS Four active components such as gentiopicroside， swertiamarin， swertioside and amarogentin were detected in the roots and rhizomes of G. rigescens and G. cephalantha， and the contents of the four components were similar in both. The contents of gentiopicroside in the root and rhizome of G. cephalantha and G.rigescens were more than four times of the limit standard of the Chinese Pharmacopoeia （Part Ⅰ） in 2020； However， only swertiamarin， swertioside and amarogentin were detected in the roots and rhizomes of G.delavayi， and the contents of swertioside and amarogentin were 34.12 and 8.81 times of those of G. rigescens， respectively. In addition， a total of 33 compounds 术。E-mail：515227235@qq.com were identified from the roots and rhizomes of 3 plants of Gentiana by UPLC-ESI-Q-TOF-MS， mainly iridoids. Additionally， G. rigescens and G. cephalantha contained xantones， G. delavayi contained flavonoids. PCA showed that there was a small difference between G. rigescens and G. cephalantha； however， there was a big difference between G. delavayi and G. rigescens. CONCLUSIONS The difference between the roots and rhizomes of G. cephalantha and G. rigescens from the same origin is small and there is substitutability； while the difference in the chemical components from roots and rhizomes between G. delavayi and G. rigescens is great and G. delavayi cannot be used as medicine instead of G. rigescens.

OBJECTIVETo investigate the effect of high-intensity focused ultrasound (HIFU) and gemcitabine on xenograft growth in nude mice bearing human pancreatic cancer.

METHODSNude mouse models bearing subcutaneous human pancreatic cancer cell line PANC-1 xenograft were randomized into 4 groups, including a control group and 3 treatment groups subjected to treatments with HIFU, gemcitabine, or both. After the treatments, the tumor was measured on a weekly basis for 5 weeks, and the tumor growth curve was drawn. The tumor inhibition rate was calculated and the expression of vascular endothelial growth factor (VEGF) in the tumor tissue was examined by immunohistochemistry.

RESULTSThe tumor volume showed significant differences between the 3 treatment groups (P<0.01), but all significantly smaller than that in the control group; HIFU combined with gemcitabine resulted in the most obvious reduction in the tumor volume. VEGF expression in the tumor tissue was the lowest in the combined treatment group and the highest in the control group.

CONCLUSIONHIFU therapy produces definite therapeutic effect on human pancreatic cancer in the nude mouse model, and its combination with chemotherapy is the optimal treatment modality.

Animals ; Cell Line, Tumor ; Combined Modality Therapy ; Deoxycytidine ; analogs & derivatives ; therapeutic use ; High-Intensity Focused Ultrasound Ablation ; Humans ; Immunohistochemistry ; Mice ; Mice, Nude ; Pancreatic Neoplasms ; therapy ; Transplantation, Heterologous ; Vascular Endothelial Growth Factor A ; metabolism

Objective To investigate the effect of high-intensity focused ultrasound (HIFU) and gemcitabine on xenograft growth in nude mice bearing human pancreatic cancer. Methods Nude mouse models bearing subcutaneous human pancreatic cancer cell line PANC-1 xenograft were randomized into 4 groups, including a control group and 3 treatment groups subjected to treatments with HIFU, gemcitabine, or both. After the treatments, the tumor was measured on a weekly basis for 5 weeks, and the tumor growth curve was drawn. The tumor inhibition rate was calculated and the expression of vascular endothelial growth factor (VEGF) in the tumor tissue was examined by immunohistochemistry. Results The tumor volume showed significant differences between the 3 treatment groups (P<0.01), but all significantly smaller than that in the control group; HIFU combined with gemcitabine resulted in the most obvious reduction in the tumor volume. VEGF expression in the tumor tissue was the lowest in the combined treatment group and the highest in the control group. Conclusion HIFU therapy produces definite therapeutic effect on human pancreatic cancer in the nude mouse model, and its combination with chemotherapy is the optimal treatment modality.

Objective To investigate the effect of high-intensity focused ultrasound (HIFU) and gemcitabine on xenograft growth in nude mice bearing human pancreatic cancer. Methods Nude mouse models bearing subcutaneous human pancreatic cancer cell line PANC-1 xenograft were randomized into 4 groups, including a control group and 3 treatment groups subjected to treatments with HIFU, gemcitabine, or both. After the treatments, the tumor was measured on a weekly basis for 5 weeks, and the tumor growth curve was drawn. The tumor inhibition rate was calculated and the expression of vascular endothelial growth factor (VEGF) in the tumor tissue was examined by immunohistochemistry. Results The tumor volume showed significant differences between the 3 treatment groups (P<0.01), but all significantly smaller than that in the control group; HIFU combined with gemcitabine resulted in the most obvious reduction in the tumor volume. VEGF expression in the tumor tissue was the lowest in the combined treatment group and the highest in the control group. Conclusion HIFU therapy produces definite therapeutic effect on human pancreatic cancer in the nude mouse model, and its combination with chemotherapy is the optimal treatment modality.

Marked by the Third Plenary Session of the Eleventh Central Committee of the CPC, Shanghai health care started a journey of reform and opening up as with other sectors. This essay reviews various stages Shanghai health care experienced and the achievements for the last 30 years since reform and opening up, and analyzes the challenges Shanghai health care faces currently. On this basis, the essay summaries the experiences and lessons learned from Shanghai health care reform and development.

Under the general requirements of China's national health reform, the basic framework of Shanghai's health reform was constructed at five different aspects the long term vision, goal, strategies, measures, supportive reform activities. The general thought of Shanghai's health reform can be concluded into two aspects: first, establishing a basic healthcare system of covering both urban and rural residents universally; second, enhancing the foundation of enabling sustainable health development.